2024-Present: Expanded Indications Under Investigation Multiple ongoing trials evaluate tirzepatide for: SUMMIT: Cardiovascular outcomes in obesity with heart failure SYNERGY-NASH: Metabolic dysfunction-associated steatohepatitis showing significant fibrosis improvement [6] SURMOUNT-OSA: Obstructive sleep apnea treatment SURPASS-CVOT: Major adverse cardiovascular events in diabetes with established CVD [7] Molecular Characteristics Landmark Clinical Findings Weight Loss Tirzepatide produces the most substantial weight reductions ever documented for a pharmacological obesity intervention: SURMOUNT-1 (non-diabetes): Mean weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs
Pennsylvania is planning to limit Medicaid coverage to beneficiaries at the highest risk of complications from obesity
J-EG-M declares that he has received honoraria for lectures for AstraZeneca, Bayer, Boheringer Ingelheim, Merck, and Xinetixs Pharma
These include reduced GHRH or ghrelin secretion, greater somatostatin inhibition, greater somatotroph sensitivity to IGF-I feedback, reduced pituitary responsiveness to GHRH, and reduced pituitary or hypothalamic responsiveness to ghrelin
Complete the Cora Health online health assessment at trycora.io
Actually, decreased GSH levels are known to activate NF-B transcription factor, which has been shown to bind and activate genes controlled by the HIV long terminal repeat (Staal, 1998), and thus may affect viral replication